EQ - Equillium, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.6300
-0.0300 (-0.82%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.6600
Open3.6400
Bid3.5800 x 800
Ask3.9500 x 800
Day's Range3.6300 - 3.6300
52 Week Range3.1000 - 19.6900
Volume4
Avg. Volume25,733
Market Cap63.076M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.4130
Earnings DateNov 10, 2019 - Nov 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update

    Equillium, Inc. (EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced it has initiated the EQUALISE Phase 1b clinical trial of itolizumab (EQ001) in patients with lupus nephritis and provided an update on its ongoing clinical programs. Additionally, Equillium announced an agreement with Silicon Valley Bank and Oxford Finance to secure a term loan for up to $20 million, and that the company has secured exclusive rights to negotiate licensing rights with third parties to develop and commercialize itolizumab in select major markets outside of North America.

  • Will Equillium, Inc. (NASDAQ:EQ) Need To Raise More Money?
    Simply Wall St.

    Will Equillium, Inc. (NASDAQ:EQ) Need To Raise More Money?

    Equillium, Inc. (NASDAQ:EQ) continues its loss-making streak, announcing negative earnings for its latest financial...

  • GlobeNewswire

    Equillium to Host Business Update Call on October 1, 2019

    Equillium, Inc. (EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders will be hosting a call with shareholders and the investment community to provide a business update on Tuesday, October 1, 2019.  Dan Bradbury, Equillium’s chairman and chief executive officer, and other members of Equillium’s management team will participate in the call. During the call the Company plans to provide an update on its clinical development programs and corporate milestones.

  • GlobeNewswire

    Equillium to Present at H. C. Wainwright 21st Annual Global Investment Conference

    LA JOLLA, Calif., Aug. 27, 2019 -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to.

  • GlobeNewswire

    Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights

    Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Drug (IND) application accepted by.

  • GlobeNewswire

    Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma

    Equillium, Inc. (EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced it has initiated the EQUIP Phase 1b clinical trial of its CD6 targeted therapy, itolizumab (EQ001), in patients with uncontrolled moderate to severe asthma. “There continues to be a need for new therapies to treat patients with uncontrolled asthma, many of whom continue to experience symptoms despite the use of current standard of care treatments including bronchodilators and inhaled corticosteroids and in some cases, existing targeted biologics. Given the heterogeneous and complex biology of this disease, there is a need for novel targeted therapies with unique mechanisms of action that could be effective across the spectrum of asthma phenotypes, regardless of eosinophil levels,” said Prof. Jo Douglass, M.D., head of Immunology and Allergy at Royal Melbourne Hospital and principal investigator of the EQUIP Phase 1b study.

  • GlobeNewswire

    Equillium to Present at Jefferies 2019 Healthcare Conference

    LA JOLLA, Calif., May 23, 2019 -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to.

  • GlobeNewswire

    Equillium Reports First Quarter 2019 Financial Results and Recent Highlights

    EQUATE Phase 1b/2 trial in acute graft-versus-host disease (aGVHD) ongoing with data expected in 1Q 2020 On track to initiate Phase 1b proof-of-concept trials of itolizumab.

  • GlobeNewswire

    Equillium Expands Scientific and Clinical Advisory Team

    “We’ve assembled an exemplary group of well-respected, industry-leading scientific and clinical advisors with decades of combined experience in immunology, rheumatology, clinical development and business strategy,” said Daniel Bradbury, chairman and chief executive officer of Equillium.

  • GlobeNewswire

    Equillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day

    LA JOLLA, Calif., April 16, 2019 -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that.

  • GlobeNewswire

    Equillium to Present at H.C. Wainwright Global Life Sciences Conference

    LA JOLLA, Calif., March 28, 2019 -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that.

  • GlobeNewswire

    Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

    LA JOLLA, Calif., March 27, 2019 -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe.

  • GlobeNewswire

    Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis

    Equillium, Inc. (EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it plans to develop EQ001 for the treatment of lupus nephritis (LN). Equillium remains on track to initiate the EQUATE Phase 1b/2 trial in acute graft-versus-host disease (aGVHD) in the first quarter of 2019 and initiate a proof-of-concept trial in severe asthma in the second quarter of 2019.

  • GlobeNewswire

    Equillium to Present at Leerink Partners Global Healthcare Conference

    LA JOLLA, Calif., Feb. 21, 2019 -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, announced today that.

  • GlobeNewswire

    Equillium to Host Business Update Call on February 26

    Equillium, Inc. (EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, will be hosting a call with shareholders and the investment community to provide a business update on Tuesday, February 26, 2019.  Daniel M. Bradbury, Equillium’s chairman and chief executive officer and other members of Equillium’s management team will participate in the call.

  • GlobeNewswire

    Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease

    Equillium, Inc. (EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designations for EQ001 for both the prevention and treatment of acute graft-versus-host disease (aGVHD). The FDA’s Orphan Drug designation program provides incentives to companies developing therapeutics for the safe and effective treatment, diagnosis or prevention of rare diseases and disorders that affect fewer than 200,000 people in the United States.

  • GlobeNewswire

    Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease

    Equillium, Inc. (EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EQ001 for the treatment of acute graft-versus-host disease (aGVHD). The Company is planning to initiate a Phase 1b/2 clinical trial in early 2019, called the EQUATE trial, which will evaluate EQ001 for the treatment of patients presenting with aGVHD.

  • GlobeNewswire

    Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights

    Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation of Phase 1b/2 Trial of EQ001 in Acute.

  • GlobeNewswire

    Equillium to Present at Investor Conferences in November 2018

    LA JOLLA, Calif., Nov. 01, 2018 -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe.